Michael Gelband’s Organogenesis Holdings ORGO Stock Holding History

Michael Gelband’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$556K	Sell	228,834 -48,080	-17%	-$117K	﹤0.01%	1215
2026 Q1	$656K	Buy	+276,914	New	+$959K	0.01%	1119
2023 Q4	–	Sell	-123,737	Closed	-$393K	–	1901
2023 Q3	$393K	Sell	123,737 -870,887	-88%	-$2.77M	﹤0.01%	1321
2023 Q2	$3.3M	Sell	994,624 -25,777	-3%	-$76.2K	0.03%	598
2023 Q1	$2.17M	Buy	1,020,401 +845,648	+484%	+$2.09M	0.02%	841
2022 Q4	$470K	Sell	174,753 -5,702	-3%	-$16.6K	0.01%	1197
2022 Q3	$585K	Buy	180,455 +165,360	+1,095%	+$747K	0.01%	1311
2022 Q2	$74K	Sell	15,095 -89,721	-86%	-$552K	﹤0.01%	1768
2022 Q1	$799K	Buy	104,816 +90,412	+628%	+$700K	0.01%	1284
2021 Q4	$133K	Buy	+14,404	New	+$153K	﹤0.01%	1908
2021 Q3	–	Sell	-29,862	Closed	-$496K	–	2494
2021 Q2	$496K	Buy	+29,862	New	+$557K	0.01%	1441

Other funds holding ORGO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Michael Gelband's ORGO Position: Q2 2026 in Review

Michael Gelband reduced its Organogenesis Holdings (ORGO) stake by 17% in Q2 2026, selling an estimated $117K and leaving 228,834 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

Michael Gelband first reported a position in ORGO in Q2 2021 and has held it in 11 quarters since. The position peaked at $3.3M in Q2 2023. 134 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

Michael Gelband held 228,834 shares of Organogenesis Holdings worth $556K as of Q2 2026.
Michael Gelband sold 48,080 Organogenesis Holdings shares in Q2 2026, an estimated $117K.
Organogenesis Holdings made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1215 holding.
Michael Gelband first reported a position in Organogenesis Holdings in Q2 2021 and has held it in 11 quarters since.
Michael Gelband's Organogenesis Holdings position peaked at $3.3M in Q2 2023.
134 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.